HR-positive, HER2-negative breast cancer
Clinical trials for HR-positive, HER2-negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR-positive, HER2-negative breast cancer trials appear
Sign up with your email to follow new studies for HR-positive, HER2-negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Two-Drug combo outsmart Treatment-Resistant breast cancer?
Disease control OngoingResearchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Breast cancer patients monitored for years in new safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise in Late-Stage breast cancer trial
Disease control OngoingThis Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New pill combo aims to keep breast cancer from returning
Disease control OngoingThis Phase III trial tests whether adding the experimental drug TQB3616 to standard hormone therapy can help prevent breast cancer from returning in women with HR-positive, HER2-negative breast cancer after surgery. About 1,946 women will receive either TQB3616 or a placebo, plus…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill targets MYC cancers in early trial
Disease control OngoingThis study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participa…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 1/2 • Sponsor: Monte Rosa Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC